Cargando…

Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy

• Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furlan, Anna, Forner, Gabriella, Cipriani, Ludovica, Vian, Elisa, Rigoli, Roberto, Gherlinzoni, Filippo, Scotton, Piergiorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139434/ https://www.ncbi.nlm.nih.gov/pubmed/34217677 http://dx.doi.org/10.1016/j.clml.2021.05.013

Ejemplares similares

COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
por: Furlan, Anna, et al.
Publicado: (2021)

Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution
por: Furlan, Anna, et al.
Publicado: (2022)

Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
por: Chavda, Vivek P., et al.
Publicado: (2023)

Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19
por: Nnaji, Chukwudi Arnest, et al.
Publicado: (2020)

COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma
por: Colombo, Daniele, et al.
Publicado: (2022)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma
por: Vandeberg, Peter, et al.
Publicado: (2021)

Severe COVID-19 Complicated by Cerebral Venous Thrombosis in a Newborn Successfully Treated with Remdesivir, Glucocorticoids, and Hyperimmune Plasma
por: Cursi, Laura, et al.
Publicado: (2021)

Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
por: Ali, Shaukat, et al.
Publicado: (2021)

Development of an ELISA for distinguishing convalescent sera with Mycoplasma hyopneumoniae infection from hyperimmune sera responses to bacterin vaccination in pigs
por: Ding, Honglei, et al.
Publicado: (2021)

Dramatic Response of Lupus Enteritis, Nephritis, and Pancytopenia to Plasmapheresis and Rituximab
por: Aftab, Adan, et al.
Publicado: (2022)

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies
por: Magyari, Ferenc, et al.
Publicado: (2022)

Acquired Isolated Factor VII Deficiency in Plasma Cell Dyscrasias: A Brief Presentation of Two Plasma-Cell-Leukemia-Related Cases and Review of Literature
por: Furlan, Anna, et al.
Publicado: (2023)

Convalescent-anti-SARS-CoV-2-plasma/remdesivir/rituximab: COVID-19 infection, and lack of efficacy following off-label use: 20 case reports
Publicado: (2022)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

PB2276: EARLY ADMINISTRATION OF REMDESIVIR PLUS CONVALESCENT PLASMA THERAPY IS EFFECTIVE TO TREAT COVID-19 PNEUMONIA IN B-CELL DEPLETED PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Pinczes, L. I., et al.
Publicado: (2022)

ANTI-DNA ANTIBODIES IN HYPERIMMUNIZED RABBITS
por: Christian, Charles L., et al.
Publicado: (1965)

Hyperimmune Globulins for the Management of Infectious Diseases
por: Pati, Ilaria, et al.
Publicado: (2023)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximab: Depletion of B-lymphocytes, lack of efficacy and off label treatment: case report
Publicado: (2022)

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
por: Mair-Jenkins, John, et al.
Publicado: (2015)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India
por: Sharma, Dibya J, et al.
Publicado: (2021)

Rituximab: B cell depletion: case report
Publicado: (2021)

RHEUMATOID FACTOR PROPERTIES OF HYPERIMMUNE RABBIT SERA
por: Christian, Charles L.
Publicado: (1963)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical Analysis
por: Voit, Katja, et al.
Publicado: (2021)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Development of an indirect ELISA for detecting humoral immunodominant proteins of Mycoplasma hyopneumoniae which can discriminate between inactivated bacterin-induced hyperimmune sera and convalescent sera
por: Ding, Honglei, et al.
Publicado: (2019)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

B Cell Depletion: Rituximab in Glomerular Disease and Transplantation
por: Marinaki, S., et al.
Publicado: (2013)

Convalescent-anti-sars-cov-2-plasma/remdesivir: Lack of efficacy following: 2 case reports
Publicado: (2022)

GAMMA GLOBULIN TURNOVER IN RABBITS BEFORE AND DURING HYPERIMMUNIZATION
por: Andersen, Stig Bryde, et al.
Publicado: (1964)

Prevention and Treatment of Influenza with Hyperimmune Bovine Colostrum Antibody
por: Ng, Wy Ching, et al.
Publicado: (2010)

Herd immunity: hyperimmune globulins for the 21st century
por: Elliott, Sarah TC, et al.
Publicado: (2018)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review
por: Liao, Sih-Han, et al.
Publicado: (2017)

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
por: Damianaki, Anthie, et al.
Publicado: (2022)

Bendamustine/remdesivir/rituximab: Lymphocytopenia, hypogammaglobulinaemia and rebound viral shedding following drug resistance: case report
Publicado: (2022)

Dexamethasone/remdesivir/rituximab: Hypotension, dyspnoea and lack of efficacy following off-label use: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rrvlp9u7eiiuom564td2tfus7c